lncRNA SOX2OT rs9839776 多态性与韩国人胃癌风险的关联:病例对照研究。
Association of lncRNA SOX2OT rs9839776 polymorphism with gastric cancer risk in Korean: Case-control study.
发表日期:2023 Oct 27
作者:
Jang Hee Hong, Eun-Heui Jin, Jae Kyu Sung, In Ae Chang, Hyojin Kang, Sang-Il Lee
来源:
CLINICAL PHARMACOLOGY & THERAPEUTICS
摘要:
长链非编码 RNA SRY-box 转录因子 2 重叠转录物 (SOX2OT) 的异常调节在包括胃癌 (GC) 在内的多种疾病中都有报道。然而,SOX2OT 中经过充分研究的 rs9839776 单核苷酸多态性与 GC 易感性之间的关联尚未报道。本研究旨在评估 SOX2OT 中 rs9839776 单核苷酸多态性与 GC 风险之间的关联。使用 TaqMan 基因分型测定对 460 名 GC 患者和 386 名对照者进行了 rs9839776 的基因分型。我们发现显性模型 (CT TT) 和 rs9839776 T 等位基因与 GC 风险降低显着相关(P = .046,调整优势比 [AOR] = 0.72,95% 置信区间 [CI] = 0.52-1.00,P = .044,AOR = 0.74,95% CI = 0.56-0.99,分别)。此外,分层分析显示,显性模型(CT TT)和rs9839776 T等位基因与淋巴结转移阴性风险降低显着相关(P = .039,AOR = 0.67,95% CI = 0.46-0.98,P = .049,AOR = 0.71,95% CI = 0.51-1.00)和肿瘤分期 I (A B)/II (A B C)(P = .028,AOR = 0.66,95% CI = 0.50-0.96,P = 。 041,AOR = 0.71,95% CI = 0.52-0.99)GC。我们的研究结果表明 rs9839776 T 等位基因可能是对抗 GC 易感性的保护因素。需要进一步研究来阐明 rs9839776 是否影响 SOX2OT 表达。版权所有 © 2023 作者。由 Wolters Kluwer Health, Inc. 出版
Aberrant regulation of the long non-coding RNA SRY-box transcription factor 2 overlapping transcript (SOX2OT) has been reported in various diseases including gastric cancer (GC). However, an association between the well-studied rs9839776 single nucleotide polymorphism in SOX2OT and GC susceptibility has not been reported. This study aimed to evaluate the association between the rs9839776 single nucleotide polymorphism in SOX2OT and GC risk. Genotyping of rs9839776 was conducted using TaqMan genotyping assay for 460 patients with GC and 386 controls. We found that the dominant model (CT+TT) and rs9839776 T allele were significantly associated with decreased GC risk (P = .046, adjusted odds ratio [AOR] = 0.72, 95% confidence interval [CI] = 0.52-1.00 and P = .044, AOR = 0.74, 95% CI = 0.56-0.99, respectively). In addition, stratified analysis revealed that the dominant model (CT+TT) and rs9839776 T allele were significantly associated with decreased risk of lymph node metastasis-negative (P = .039, AOR = 0.67, 95% CI = 0.46-0.98 and P = .049, AOR = 0.71, 95% CI = 0.51-1.00, respectively) and tumor stage I (A+B)/II (A+B+C) (P = .028, AOR = 0.66, 95% CI = 0.50-0.96 and P = .041, AOR = 0.71, 95% CI = 0.52-0.99, respectively) GC. Our findings suggest that the rs9839776 T allele may be a protective factor against GC susceptibility. Further research is needed to clarify whether rs9839776 affects SOX2OT expression.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.